IMS Health’s Yan Shangjun On China’s Changing Diabetes Market: An Interview With PharmAsia News
This article was originally published in PharmAsia News
IMS Health Inc. Pharma Insight Principal Yan Shangjun sits down with PharmAsia News to talk about the evolution of China’s diabetes market and how opinions of Chinese doctors affect the market.
You may also be interested in...
More than half of a 26-member advisory committee supports eliminating or easing the REMS for GSK’s diabetes drug, but the spilt vote and high-profile of the product’s safety issues suggest that FDA is unlikely to modify Avandia’s risk management.
J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.